AACR-Amgen Fellow Uncovers Targets to Mitigate Treatment Resistance in Multiple Myeloma
2019 AACR-Amgen Fellow, Julia Frede, PhD, reported in Nature Cell Biology, how treatment can induce the expression of a distinct set of actionable immunotherapy targets in multiple myeloma, such as CXCR4, which can be exploited to keep treatment resistance at bay.